Rheumatoid Arthritis Drugs Market Size, Share, Report By 2032

The global rheumatoid arthritis drugs market size was valued at US$ 61 billion in 2023 and is projected to hit US$ 71.14 billion by 2032 with a registered CAGR of 1.60% from 2023 to 2032.

The increased prevalence of rheumatoid arthritis is one of the major reasons driving the global rheumatoid arthritis medications market. According to a study published in November 2020, the global prevalence of rheumatoid arthritis was anticipated to be 0.46% based on a systematic review. As a result, more rheumatoid arthritis treatments will be prescribed, propelling the market for these medications forward. Increased launches of novel biologics and rising generic medicine penetration are projected to boost the global rheumatoid arthritis pharmaceuticals market significantly.

Get the Sample Pages of Report@ https://www.precedenceresearch.com/sample/1755

Growing patient knowledge of rheumatoid arthritis problems is another factor driving the global rheumatoid arthritis medications market. The worldwide rheumatoid arthritis medications industry is also being propelled forward by government authorities’ increasing efforts.

Report Highlights

On the basis of molecule type, biologics segment holds the largest market share in the global rheumatoid arthritis drugs market. Biological pharmaceuticals are expected to account for the majority of revenue in established nations over the predicted period. Due to the high cost of biologics, these treatments face significant competition from biosimilars and generic pharmaceuticals in emerging nations.
On the basis of sales channel, prescription drugs segment holds the largest market share in the global rheumatoid arthritis drugs market. Overuse of rheumatoid arthritis drugs for a long time can develop to treatment resistance, thus patients with this disorder should see a rheumatologist and follow their recommendations.

Regional Snapshot

North America region is the fastest growing region in the rheumatoid arthritis drugs market. The U.S. hold the highest market share in the North America rheumatoid arthritis drugs market. According to the Centers for Disease Control and Prevention, arthritis affects approximately one in every four Americans, or 58.5 million people. In addition, the Canadian government estimates that 374,000 Canadians aged 16 and up suffer from rheumatoid arthritis. Because of the disease’s extensive prevalence, more medicines will be taken, leading in a growth in the rheumatoid arthritis drugs market in North America.

Asia-Pacific is the largest segment for rheumatoid arthritis drugs market in terms of region.China and Indiaare dominating the rheumatoid arthritis drugs market in the Asia-Pacific region. Rising knowledge of disease remission therapy, high public and private healthcare expenditure, and rising rheumatoid arthritis incidences are all driving the Asia-Pacific rheumatoid arthritis medications market. Furthermore, easy access to high-quality healthcare, a solid clinical product range, favorable reimbursement standards, and the approval of novel medications are projected to boost revenue growth in the Asia-Pacific area.

Table of Contents

Rheumatoid Arthritis Drugs Market Scope

Report Coverage	Details
Market Size by 2032	USD 71.14 Billion
Growth Rate from 2023 to 2032	CAGR of 1.60%
Largest Market	North America
Fastest Growing Market	Asia-Pacific
Base Year	2022
Forecast Period	2023 to 2032
Segments Covered	Molecule, Sales Channel, Route of Administration, Geography

Rheumatoid Arthritis Drugs Market Dynamics

Drivers

Surge in prevalence of rheumatoid arthritis

The ageing population is mainly accountable for the rising incidences of rheumatoid arthritis. Furthermore, some evidence suggests that smokers are more likely to develop rheumatoid arthritis. The rise in the senior population, higher usage of traditional disease modifying antirheumatic drugs, and government measures to disseminate awareness of rheumatoid arthritis symptoms are the primary drivers driving the growth of global rheumatoid arthritis drugs market.

Restraints

Lack of awareness and high cost of rheumatoid arthritis drugs

The key limits of the global rheumatoid arthritis drugs market are expected to be medication related undesirable effects and high pricing of biological disease modifying antirheumatic drugs therapy. The most significant market limitation is the high cost of pharmaceuticals, as therapy is far more expensive and the average person cannot afford it in cases where there is no cure for the disease. The global rheumatoid arthritis drugs market is projected to face challenges due to a lack of awareness, particularly in emerging nations.

Opportunities

Growing advancements in biologics

Theadvances in sophisticated biologics, increased purchasing power, increased healthcare expenditure, and worldwide access to high quality medications for middle and poor class families are all contributing factors. On the other hand, due to enhanced treatment regarding early treatment and screening of rheumatoid arthritis, the global rheumatoid arthritis drugs market is predicted to rise quickly and shift the market outlook. As a result, growing advancements in biologics is creating lucrative opportunities for the growth of global rheumatoid arthritis drugs market.

Challenges

Lack of resources in underdeveloped nations

The underdeveloped countries do not have enough resources for the development of rheumatoid arthritis drugs. As a result, lack of resources in underdeveloped nations is a major challenge for the expansion of worldwide rheumatoid arthritis drugs market.

Rheumatoid Arthritis Drugs Market Companies

AbbVie
Boehringer Ingelheim GmbH
Novartis AG
Regeneron Pharmaceuticals, Inc.
Pfizer, Inc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
UCB S.A.
Johnson & Johnson Services, Inc.
Amgen, Inc.

Segments Covered in the Report

By Molecule

Pharmaceuticals
- NSAIDs
- Analgesics
- DMARDs
- Glucocorticoids
Biopharmaceuticals
- Biologics
  - TNF-α antagonists
  - T-cell inhibitors
  - CD20 antigen
  - JAK inhibitors
  - anti-IL6 biologics
- Biosimilars
  - CD20 antigen
  - TNF-α antagonists

By Sales Channel

Prescription
Over-the-Counter (OTC)

By Route of Administration

Oral
Parenteral

By Geography

North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa